文献速递类风湿关节炎

JAK抑制剂二线治疗类风湿关节炎患者的持续疗效:来自ANSWER队列的见解

Sustained efficacy of second-line JAK inhibitors in patients with rheumatoid arthritis: insights from the ANSWER cohort.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

这项多中心回顾性研究基于日本观察性登记数据,分析5900个治疗疗程(4046例未用过bDMARD/JAKi,1854例二线治疗),比较bDMARD和JAKi一线与二线使用的药物续用率和疗效差异。结果显示,仅JAKi在一线和二线治疗间药物停药的累积发生率函数无显著差异,且JAKi二线治疗的续用率和疗效与一线相似,而其他药物二线治疗影响续用率。作者认为JAKi可能优于bDMARDs用于需要更换初始治疗的RA患者。

要点

  • 仅JAKi在一线和二线治疗间药物停药的累积发生率函数无显著差异。
  • 竞争风险分析显示,除JAKi外,二线治疗影响所有药物的续用率。
  • 线性混合模型分析中,JAKi二线治疗与一线治疗疗效相似,不同于其他药物。

核心结论

  • JAKi二线治疗维持了与一线治疗相似的续用率和疗效,对于需要更换初始治疗的RA患者可能优于bDMARDs。

研究设计与样本

  • 多中心回顾性研究,分析日本观察性多中心登记中5900个治疗疗程(4046例未用过bDMARD/JAKi,1854例二线治疗)。

主要发现

  • 在TNF抑制剂、IL-6抑制剂、CTLA4和JAKi中,仅JAKi在一线和二线治疗间药物停药的累积发生率函数无显著差异。
  • 竞争风险分析显示,与累积发生率函数分析一致,除JAKi外,二线治疗影响所有药物的续用率。
  • 线性混合模型分析显示,JAKi二线治疗与一线治疗疗效相似,不同于其他药物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This multicentre, retrospective study aimed to evaluate differences in drug continuation rates and efficacy between first- and second-line use of biological DMARDs (bDMARDs) and Janus kinase inhibitors (JAKi) after failure of the initial therapy in real-world RA settings. METHODS: Data from an observational multicentre registry of patients with RA in Japan were analysed, encompassing 5900 treatment courses (4046 bDMARD/JAKi-naïve cases and 1854 second-line cases). Gray's tests were used to compare the cumulative incidence function (CIF) for drug discontinuation, considering discontinuation due to remission as a competing risk. Competing risk analysis using Fine-Gray model was conducted to analyse the hazard ratios after adjusting for potential confounders. Changes in the Clinical Disease Activity Index (ΔCDAI) and disease activity score (ΔDAS28-CRP) were assessed at each time point compared with baseline using a linear mixed model with covariate adjustments. RESULTS: Among the TNF inhibitors, IL-6 inhibitors, Cytotoxic T-lymphocyte associated protein 4 (CTLA4) and JAKi, only JAKi showed no significant difference in CIF of first- and second-line treatments. Competing risk analysis showed that consistent with the CIF analysis, second-line treatment influenced the drug continuation rates for all drugs except for JAKi. In analysing CDAI and DAS28-CRP trends using a linear mixed model, JAKi demonstrated similar efficacy as first- and second-line therapy, unlike other drugs. CONCLUSIONS: JAKi maintained continuation rates and efficacy in second-line treatment compared with first-line treatment, which is potentially advantageous over bDMARDs for patients with RA who require a change in initial therapy.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Tsujimoto K, Ebina K, Okamura S, et al. Sustained efficacy of second-line JAK inhibitors in patients with rheumatoid arthritis: insights from the ANSWER cohort. Rheumatology (Oxford). 2025. PMID: 40111839. doi:10.1093/rheumatology/keaf157

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。